AtaiBeckley (ATAI) Jefferies 2024 Global Healthcare Conference summary

Company overview and strategy

• Focuses on mental health disorders with unmet needs, using innovative approaches and a hub-and-spoke model with subsidiaries and strategic investments.

• Pipeline now centers on four core assets, with additional strategic stakes in Beckley and Compass.

• Emphasis on psychedelics and interventional psychiatry, with a notable program in cognitive impairment and schizophrenia expecting phase II-B data next year.

• Leadership transition to a CEO role aligns with a shift to a more streamlined, execution-focused structure.

• Cash runway extends to 2026, supporting multiple phase II trials.

Industry and regulatory landscape

• Recent clinical data from peers (Compass, MindMed) show efficacy for psychedelics in mental health, supporting sector momentum.

• Regulatory environment remains favorable, with more breakthrough designations and successful end-of-phase II meetings.

• Spravato’s commercial success ($1B expected) is building infrastructure for the field.

• Recent FDA AdCom for MDMA resulted in a negative vote, highlighting trial design and data quality issues.

Clinical trial design and lessons from MDMA AdCom

• MAPS’ MDMA trials faced criticism for small size, selection bias, lack of safety labs, and inadequate abuse potential assessment.

• Functional unblinding is a known challenge in psychedelic trials; dose-response data can help address this.

• Manualized therapy in MAPS’ trials complicated regulatory review; current studies avoid non-standardized therapy, focusing on psychological support and standard care.

• Abuse potential is addressed by capturing adverse events of special interest and conducting human abuse potential studies.